ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Comment by kmuchaon May 09, 2018 10:14pm

114 Views

Post# 28008993

RE:RE:RE:RE:RE:RE:Sale

haha ya I hear ya man.

I would love some legitimate news to get excited about here pretty soon. A partnership would be pretty solid right around now, but so would a multi-billion $ buyout haha. Pipe dream right now I know. Maybe we need to get PMN 310 into the clinic to show how good it is? Maybe white papers aren't good enough? I wish I had the answers!!

Bullboard Posts

5 steps to mastering risk management in the stock market